Gilles Salles

Gilles Salles

UNVERIFIED PROFILE

Are you Gilles Salles?   Register this Author

Register author
Gilles Salles

Gilles Salles

Publications by authors named "Gilles Salles"

Are you Gilles Salles?   Register this Author

100Publications

3140Reads

30Profile Views

Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19.

Haematologica 2019 Oct 13;104(10):e487-e488. Epub 2019 Jun 13.

Hospices Civils de Lyon, service d'hématologie biologique

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.225557DOI Listing
October 2019

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

Genet Epidemiol 2019 10 13;43(7):844-863. Epub 2019 Aug 13.

Center for Neuroengineering and Therapeutics, Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gepi.22242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763347PMC
October 2019

Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort.

Cancers (Basel) 2019 Oct 4;11(10). Epub 2019 Oct 4.

Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'hématologie, 69495 Pierre Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11101495DOI Listing
October 2019

Actualités dans les lymphomes à petites cellules non folliculaires.

Presse Med 2019 Jul - Aug;48(7-8 Pt 1):859-870. Epub 2019 Aug 22.

Inserm U1052 CNRS 5286, centre de recherche en cancérologie de Lyon (CRCL), équipe « clinical and experimental models of lymphomagenesis », 69600 Lyon, France; Université de Lyon, université Claude-Bernard Lyon 1, faculté de médecine et de maïeutique Lyon-Sud-Charles-Mérieux, 69600 Lyon, France; Groupement hospitalier Sud, hospices civils de Lyon, service d'hématologie clinique, 69310 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07554982193033
Publisher Site
http://dx.doi.org/10.1016/j.lpm.2019.07.025DOI Listing
September 2019

[Follicular lymphoma: An update].

Presse Med 2019 Jul - Aug;48(7-8 Pt 1):850-858. Epub 2019 Aug 22.

Inserm U1052 CNRS 5286, centre de recherche en cancérologie de Lyon (CRCL), équipe « clinical and experimental models of lymphomagenesis », 69600 Lyon, France; Université de Lyon, université Claude-Bernard Lyon 1, faculté de médecine et de Maïeutique Lyon-Sud-Charles-Mérieux, 69600 Lyon, France; Groupement hospitalier Sud, hospices civils de Lyon, service d'hématologie clinique, 69310 Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2019.07.024DOI Listing
September 2019

New drugs for old targets.

Authors:
Gilles Salles

Hematol Oncol 2019 Jun;37 Suppl 1:101-104

Service d'Hématologie, Hospices Civils de Lyon, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2599DOI Listing
June 2019

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 May 2;19(5):275-284. Epub 2019 Jan 2.

Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183128
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.013DOI Listing
May 2019

Early-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure.

Am J Hematol 2019 Apr 4;94(4):E109-E111. Epub 2019 Feb 4.

Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25406DOI Listing
April 2019

Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma.

J Oncol Pract 2019 Mar;15(3):147-148

1 Hôpital Lyon Sud and Université Claude Bernard Lyon 1, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00089DOI Listing
March 2019

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

J Clin Oncol 2019 01 27;37(2):144-152. Epub 2018 Nov 27.

1 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud; Université de Lyon, Université Claude Bernard Lyon 1, Centre de Recherche en Cancérologie de Lyon INSERM 1052, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366812PMC
January 2019

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med 2019 01 1;380(1):45-56. Epub 2018 Dec 1.

From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent's Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) - both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell Transplant Center, Atlanta (E.K.W.); the Department of Hematology and Oncology, University Hospital of Cologne, Cologne (P.B.), and the Würzburg University Medical Center, Center for Allogeneic Stem Cell Transplantation, Würzburg (S.M.) - both in Germany; the Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City (J.P.M.); the Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna (U.J.); James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus (S.J.); the Department of Hematology and Blood and Marrow Transplant, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (C.A.); the Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (J.R.W.); Maisonneuve-Rosemont Hospital, University of Montreal, Montreal (I.F.), and the Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON (S.R.F.) - both in Canada; the Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis (V.B.); Karolinska Institutet and University Hospital, Department of Laboratory Medicine/Department of Cell Therapy and Allogeneic Stem Cell Transplantation, Stockholm (S.M.); University of Michigan Comprehensive Cancer Center, Ann Arbor (J.M.M.); the Department of Oncology, Oslo University Hospital, Oslo (H.H.); Novartis Pharma, Basel, Switzerland (S.P., O.A.); Novartis Pharmaceuticals (L.B.P., J.C.) and Novartis Institutes for BioMedical Research (R.A.), East Hanover, NJ; the Department of Hematology, Hospices Civils de Lyon, Université de Lyon, Lyon, France (G.S.); and the Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute, Portland (R.T.M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804980
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804980DOI Listing
January 2019

Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience.

Leuk Res 2019 01 29;76:29-32. Epub 2018 Nov 29.

Hospices Civils de Lyon, Department of Hematology, Lyon-Sud Hospital, Pierre-Bénite, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.016DOI Listing
January 2019

FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2018 12 13;18(12):e545-e550. Epub 2018 Jun 13.

Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; Faculté de Médecine Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon I, Pierre Bénite, France; LBMC, ENS, CNRS UMR5239, Faculté de Médecine Lyon-Sud, Pierre Bénite, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.06.006DOI Listing
December 2018

Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era.

Eur J Haematol 2018 Dec 8;101(6):774-780. Epub 2018 Oct 8.

Department of Clinical Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13167DOI Listing
December 2018

Chronic infection triggers NKT lymphomagenesis.

Blood 2018 12 2;132(25):2691-2695. Epub 2018 Nov 2.

INSERM Unité Mixte de Recherche (UMR)-S1052, Centre National de la Recherche UMR 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France-Equipe Labellisée Ligue Contre le Cancer.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-07
Publisher Site
http://dx.doi.org/10.1182/blood-2018-07-863381DOI Listing
December 2018

L’émergence des traitements par cellules CAR-T dans les lymphomes.

Bull Cancer 2018 Dec;105 Suppl 2:S168-S177

Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, 69495 Pierre Bénite cedex, France; Université Claude Bernard Lyon-1, 69100 Villeurbanne, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193004
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30047-5DOI Listing
December 2018

Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.

Leuk Lymphoma 2018 09 16;59(9):2113-2120. Epub 2018 Jan 16.

e DAME , University of Udine , Udine , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1421762DOI Listing
September 2018

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805104
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805104DOI Listing
September 2018

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

J Clin Oncol 2018 08 27;36(22):2259-2266. Epub 2018 Mar 27.

Bruce D. Cheson, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Neil Chua, University of Alberta, Edmonton, Alberta; Greg Dueck, British Columbia Cancer Agency, Kelowna; Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Jiri Mayer, University Hospital and Masaryk University, Brno; Marek Trněný, Charles University General Hospital, Prague, Czech Republic; Kamal Bouabdallah, Centre Hospitalier Universitaire Haut-Leveque, Bordeaux; Vincent Delwail, Centre Hospitalier Universitaire de Poitiers, Poitiers; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France; Nathan Fowler, University of Texas, Houston, TX; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA; John G. Gribben, Queen Mary University of London, London; Anne Lennard, Newcastle University, Newcastle upon Tyne, United Kingdom; Pieternella J. Lugtenburg, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; and Günter Fingerle-Rowson, Federico Mattiello, and Andrea Knapp, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.3656
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.3656DOI Listing
August 2018

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

J Clin Oncol 2018 08 31;36(23):2405-2412. Epub 2018 May 31.

Ajay K. Gopal, The University of Washington; Ajay K. Gopal, Fred Hutchinson Cancer Research Center, Seattle, WA; Stephen J. Schuster, Abramson Cancer Center of the University of Pennsylvania, Philadelphia; Jing-Zhou Hou, University of Pittsburgh Medical Center; Jing-Zhou Hou, University of Pittsburgh Cancer Institute, Pittsburgh; Rajendra N. Damle, Michael Schaffer, and Sriram Balasubramanian, Janssen Research & Development, Spring House, PA; Nathan H. Fowler, The University of Texas MD Anderson Cancer Center, Houston, TX; Judith Trotman, Concord Hospital, University of Sydney, Sydney, New South Wales; Andrew Spencer, Alfred Hospital-Monash University, Melbourne, Victoria; James Morton, Haematology and Oncology Clinics of Australia, Milton, Queensland, Australia; Georg Hess, Johannes Gutenberg-University, Mainz, Germany; Abdulraheem Yacoub, Kansas University Medical Center, Kansas City, KS; Michael Lill, Cedars-Sinai Medical Center, Los Angeles, CA; Peter Martin, Weill Cornell Medical College, Cornell University, New York, NY; Umberto Vitolo, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy; John Radford, University of Manchester; John Radford, Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Dolores Caballero, Hospital Clínico Universitario, Salamanca, Spain; Sanjay Deshpande, Gary J. Gartenberg, and Shean-Sheng Wang, Janssen Research & Development, Raritan, NJ; Jessica Vermeulen, Janssen Research & Development, Leiden, the Netherlands; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; and Gilles Salles, Hospices Civils de Lyon-Université de Lyon, Pierre-Bénite cedex, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.8853DOI Listing
August 2018

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.

Cancer Res 2018 07 7;78(14):4086-4096. Epub 2018 May 7.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-2900DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065509PMC
July 2018

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J Clin Oncol 2018 06 19;36(16):1603-1610. Epub 2018 Apr 19.

Matthew J. Maurer, Thomas M. Habermann, Carrie A. Thompson, Cristine Allmer, Patrick B. Johnston, Ivana N. Micallef, David J. Inwards, William R. Macon, Andrew L. Feldman, Susan L. Slager, Stephen M. Ansell, James R. Cerhan, Thomas E. Witzig, and Grzegorz S. Nowakowski, Mayo Clinic, Rochester, MN; Hervé Ghesquières and Gilles A. Salles, Université Claude Bernard, Lyon; Jean-Philippe Jais, Richard Delarue, Thierry J. Molina, Hopital Necker, Paris; Corinne Haioun, Groupe Hospitalier Mondor, Créteil; Frederic Peyrade, Centre Antoine Lacassagne, Nice; Olivier Fitoussi, Polyclinique Bordeaux Nord-Aquitaine, Bordeaux; Hervé Tilly, Centre de lutte Contre le Cancer Henri Becquerel, Rouen, France; Brian K. Link, Umar Farooq, Sergei Syrbu, and George J. Weiner, University of Iowa, Iowa City, IA; and Nicolas Ketterer, Clinique Bois-Cerf, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978469PMC
June 2018

Predictive gene-expression score for follicular lymphoma - Authors' reply.

Lancet Oncol 2018 06 1;19(6):e282. Epub 2018 Jun 1.

Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Lyon, France; Service d'Hématologie Clinique, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; Université de Lyon, Université Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, Oullins, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30339-5DOI Listing
June 2018

Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma.

Oncotarget 2018 May 4;9(34):23589-23598. Epub 2018 May 4.

Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955093PMC
May 2018

Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?

Hematol Oncol 2018 Apr 6;36(2):399-406. Epub 2017 Oct 6.

Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department, Pierre Bénite-EMR 3738, Université Lyon 1, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2479DOI Listing
April 2018

From genetics to the clinic: a translational perspective on follicular lymphoma.

Nat Rev Cancer 2018 04 9;18(4):224-239. Epub 2018 Feb 9.

Cancer Research Center of Lyon, INSERM 1052 CNRS5286, 'Clinical and experimental models of lymphomagenesis' Team, Equipe labellisée Ligue Contre le Cancer Oullins, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2017.127DOI Listing
April 2018

What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies.

Int J Mol Sci 2018 04 20;19(4). Epub 2018 Apr 20.

Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellisée LIGUE Contre le Cancer, 69008 Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms19041251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979354PMC
April 2018

Through the Glass Ceiling.

J Clin Oncol 2018 03 25;36(9):923. Epub 2018 Jan 25.

Hervé Tilly, Centre Henri Becquerel, Université de Rouen, Institut National de la Santé et de la Recherche Médicale 1245, Rouen, France; Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon-1, Institut National de la Santé et de la Recherche Médicale 1052, Pierre-Bénite, France; Thierry J. Molina, Assistance Publique-Hôpitaux de Paris, Necker, Université Paris Descartes, Paris, France; René-Olivier Casasnovas, Hôpital Le Bocage, Dijon, France; Franck Morschhauser, Université de Lille, Centre Hospitalier Universitaire Lille and Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France; and Bertrand Coiffier, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon-1, Institut National de la Santé et de la Recherche Médicale 1052, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.3961DOI Listing
March 2018

Tumor-infiltrating T lymphocytes and morphogenesis of follicular lymphoma-reply.

Hum Pathol 2018 02 8;72:198-199. Epub 2017 Nov 8.

INSERM1052, CNRS 5286, Centre de Recherche en Cancerologie de Lyon, Faculté de Médecine Lyon-Sud Charles Mérieux, Hospices Civils De Lyon, Laboratoire d'hématologie, 69495 Pierre Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2017.09.018DOI Listing
February 2018

Research protocol on early palliative care in patients with acute leukaemia after one relapse.

BMJ Support Palliat Care 2017 Dec 31;7(4):480-484. Epub 2017 Jul 31.

Clinical Research, Université Claude Bernard Lyon 1, HESPER unit EA 7425, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjspcare-2016-001173DOI Listing
December 2017

[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2017 Dec 22;104(12S):S131-S135. Epub 2017 Nov 22.

Universitätsklinikum Aachen, Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Aachen, Allemagne; Institut de cancérologie Lucien-Neuwirth, département d'hématologie clinique, Saint-Priest-en-Jarez, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.10.018DOI Listing
December 2017

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma.

Authors:
Sasha Bernatsky Héctor A Velásquez García John J Spinelli Patrick Gaffney Karin E Smedby Rosalind Ramsey-Goldman Sophia S Wang Hans-Olov Adami Demetrius Albanes Emanuele Angelucci Stephen M Ansell Yan W Asmann Nikolaus Becker Yolanda Benavente Sonja I Berndt Kimberly A Bertrand Brenda M Birmann Heiner Boeing Paolo Boffetta Paige M Bracci Paul Brennan Angela R Brooks-Wilson James R Cerhan Stephen J Chanock Jacqueline Clavel Lucia Conde Karen H Cotenbader David G Cox Wendy Cozen Simon Crouch Anneclaire J De Roos Silvia de Sanjose Simonetta Di Lollo W Ryan Diver Ahmet Dogan Lenka Foretova Hervé Ghesquières Graham G Giles Bengt Glimelius Thomas M Habermann Corinne Haioun Patricia Hartge Henrik Hjalgrim Theodore R Holford Elizabeth A Holly Rebecca D Jackson Rudolph Kaaks Eleanor Kane Rachel S Kelly Robert J Klein Peter Kraft Anne Kricker Qing Lan Charles Lawrence Mark Liebow Tracy Lightfoot Brian K Link Marc Maynadie James McKay Mads Melbye Thierry J Molina Alain Monnereau Lindsay M Morton Alexandra Nieters Kari E North Anne J Novak Kenneth Offit Mark P Purdue Marco Rais Jacques Riby Eve Roman Nathaniel Rothman Gilles Salles Gianluca Severi Richard K Severson Christine F Skibola Susan L Slager Alex Smith Martyn T Smith Melissa C Southey Anthony Staines Lauren R Teras Carrie A Thompson Hervé Tilly Lesley F Tinker Anne Tjonneland Jenny Turner Claire M Vajdic Roel C H Vermeulen Joseph Vijai Paolo Vineis Jarmo Virtamo Zhaoming Wang Stephanie Weinstein Thomas E Witzig Andrew Zelenetz Anne Zeleniuch-Jacquotte Yawei Zhang Tongzhang Zheng Mariagrazia Zucca Ann E Clarke

Lupus Sci Med 2017 12;4(1):e000187. Epub 2017 Nov 12.

Division of Rheumatology, University of Calgary, Calgary, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2016-000187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715504PMC
November 2017

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

N Engl J Med 2017 09;377(13):1250-1260

From Service d'Hématologie Clinique (S.L.G., T.G.), Service d'Anatomopathologie (A.M.), and Service d'Hématologie Biologique (M.C.B.), Hôtel-Dieu Centre Hospitalier Universitaire (CHU) de Nantes, and Centre de Recherche en Cancérologie et Immunologie (S.L.G., M.C.B.) and Faculté de Médecine (S.L.G.), Université de Nantes, Nantes, Hemato-Oncologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Université Diderot Sorbonne Paris-Cité (C.T.), Université Descartes (C.T.), Département d'Hématologie, Faculté de Médecine, Université Paris-Sud (V.R.), Département d'Anatomopathologie (D.C.) and Département d'Hématologie (O.H.), Necker Hospital, APHP, Sorbonne Paris-Cité, and INSERM Unité 1163 et Centre National de la Recherche Scientifique (CNRS) Équipe de Recherche Labellisée 8654, Imagine Institute (O.H.), Paris, Département d'Hématologie, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse (L.O.), Service d'Hématologie Clinique et Thérapie Cellulaire, CHU de Bordeaux, Bordeaux (K.B.), Service d'Hématologie et Thérapie Cellulaire, CHU de Tours, Tours (C.D.), Service d'Hématologie, CHU d'Amiens, Amiens (G.D.), INSERM, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif (V.R.), Département d'Hématologie, CHU de Nancy, Nancy (P.F.), INSERM Unité 954, Vandoeuvre (P.F.), Service d'Hématologie Clinique, CHU de Dijon, and INSERM Unité Mixte de Recherche 1231, Dijon (O.C.), Service d'Hématologie, Centre Hospitalier d'Avignon, Avignon (H.Z.), Lymphoid Malignancies Unit, Hôpital Henri Mondor, APHP, Créteil (C.H.), Service d'Hématologie du Centre Hospitalier de Vendée, La Roche-sur-Yon (H.M.), Service Hématologie Clinique (R.H.) and Département d'Hématologie (T.L.), CHU de Rennes, INSERM Unité 917 (R.H.), and INSERM Unité 1236 (T.L.), Rennes, Département d'Hematology, Centre Henri-Becquerel et Université de Normandie Unité 1245, Rouen (F.J., H.T.), Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, CHU de Clermont-Ferrand et Université Clermont Auvergne, Clermont-Ferrand (O.T.), Service d'Hématologie, Clinique Victor Hugo, Le Mans (K.L.D.), Department of Hematology, Université de Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, and CHU de Lille, Lille (F.M.), Département d'Hématologie Clinique, CHU de Montpellier, CNRS UMR 5235, Montpellier (G.C.), Service d'Oncologie et d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg (L.-M.F.), INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble Alpes (M.C., R.G.), Institute for Advanced Biosciences (M.C.), and Laboratoire de Génétique Onco-hématologie (M.C.) and Faculté de Médecine (R.G.), CHU de Grenoble Alpes, Grenoble, Service d'Hématologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite (G.S.), and Université Claude Bernard Lyon 1 and Cancer Research Center of Lyon, INSERM 1052 CNRS 5286 Lyon, Lyon (G.S.) - all in France; and Département d'Hématologie, Cliniques Universitaires Saint-Luc-Université Catholique de Louvain, Brussels (E.V.D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1701769DOI Listing
September 2017

Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding.

Oncotarget 2017 Sep 18;8(42):72818-72834. Epub 2017 Aug 18.

Anticancer Antibody Team, INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon, University of Lyon, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641171PMC
September 2017

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

J Clin Oncol 2017 Aug 20;35(22):2473-2481. Epub 2017 Apr 20.

Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6984DOI Listing
August 2017

[Clinical research activity of the French cancer cooperative network: Overview and perspectives].

Bull Cancer 2017 Jul - Aug;104(7-8):652-661. Epub 2017 Jul 5.

Groupes coopérateurs en oncologie (GCO), 10, rue de la Grange-Batelière, 75009 Paris, France; Intergroupe francophone en cancérologie thoracique (IFCT), 10, rue de la Grange-Batelière, 75009 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2017.05.006DOI Listing
August 2017

Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review.

Nucl Med Commun 2017 Jul;38(7):563-576

Department of aNuclear Medicine, University of Claude Bernard Lyon 1 bHematology, Hospices Civils de Lyon, Lyon cDepartment of Nuclear Medicine Hôpital Privé du Confluent, Nantes dDepartment of Nuclear Medicine eDepartment of Radiopharmacy, Grenoble University Hospital, Grenoble fDepartment of Nuclear Medicine, Centre Hospitalier Henri Mondor, Créteil, France gDepartment of Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000697DOI Listing
July 2017

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

J Clin Oncol 2017 Jun 29;35(17):1905-1912. Epub 2017 Mar 29.

Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.6994DOI Listing
June 2017

Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.

J Clin Oncol 2017 Jun 1;35(18):2008-2017. Epub 2017 May 1.

Camille Laurent, Nadia Amara, Georges Delsol, and Pierre Brousset, Institut Universitaire du Cancer-Oncopole de Toulouse; Centre Hospitalier Universitaire (CHU) Toulouse; Camille Laurent, Georges Delsol, and Pierre Brousset, Institut National de la Santé et de la Recherche Médicale (INSERM), U.1037, Centre de Recherche en Cancerologie de Toulouse-Purpan, Laboratoire d'Excellence Toulouse Cancer; Thomas Filleron, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse, Toulouse; Marine Baron, Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri Mondor-Albert Chenevier; Corinne Haioun, Christiane Copie-Bergman, and Philippe Gaulard, INSERM U955, Université Paris-Est, Créteil; Mylène Dandoit, Marc Maynadié, and Laurent Martin, CHU de Dijon, Dijon; Marie Parrens, Beatrice Vergier, and Antoine de Mascarel, Hôpital du Haut Lévêque, CHU de Bordeaux, Bordeaux; Bettina Fabiani, AP-HP, Hôpital Saint-Antoine; Nicole Brousse and Thierry Jo Molina, AP-HP, Hôpital Necker; Josette Brière, AP-HP, Hôpital Saint Louis; Fréderic Charlotte, AP-HP, Hôpital Pitié Salpétrière; Diane Damotte, AP-HP, Hôpitaux Universitaires Paris Centre, Paris; Alexandra Traverse-Glehen and Françoise Berger, CHU Lyon-Sud; Catherine Chassagne-Clement, Centre Léon Bérard, Lyon; Marie-Christine Copin, Univ Lille, CHU Lille, Lille; Patrick Tas, CHU de Rennes, Rennes; Marie-Christine Rousselet, CHU d'Angers, Angers; Thérèse Rousset, Hôpital Gui de Chauliac, CHU de Montpellier, Montpellier; Luc Xerri, Aix-Marseille Univ, Institut Paoli-Calmettes, Marseille; Anne Moreau and Céline Bossard, Hôpital Hôtel Dieu, CHU de Nantes, Nantes; Antoine Martin, Hôpital Avicenne, Bobigny, Bobigny; Peggy Dartigues, Institut Gustave Roussy, Villejuif; Isabelle Soubeyran, Institut Bergonié, Bordeaux; Michel Peoch, CHU de Saint Etienne, Saint Etienne; Pierre Dechelotte, CHU de Clermont-Ferrand, Clermont-Ferrand; Jean-François Michiels, CHU de Nice, Nice; Flavie Arbion, CHU de Tours, Tours; Isabelle Quintin-Roué, CHU de Brest, Brest; Jean-Michel Picquenot, Centre Henri Becquerel, CHU de Rouen, Rouen; Martine Patey, CHU de Reims, Reims; Blandine Fabre, CHU de Grenoble, Grenoble; Henri Sevestre, CHU d'Amiens, Amiens; Cécile Le Naoures, CHU de Caen, Caen; Marie-Pierre Chenard-Neu, CHU de Strasbourg, Strasbourg; Claire Bastien, CHU de Nancy, Nancy; Sylvie Thiebault, CH de Mulhouse, Mulhouse; Manuela Delage, CHU de Limoges, Limoges; Gilles Salles, Hospices Civils de Lyon, CHU Lyon-Sud; Gilles Salles, INSERM1052, Centre National de la Recherche Scientifique 5286, Université Claude Bernard, Pierre Bénite, France; Tony Petrella, Pathology University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.2083DOI Listing
June 2017

Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas.

Expert Rev Mol Diagn 2017 06 15;17(6):623-632. Epub 2017 May 15.

a Hospices Civils de Lyon, Service d'hématologie biologique , Pierre Bénite , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2017.1327811DOI Listing
June 2017

Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature.

Oncol Ther 2017 9;5(1):111-118. Epub 2017 Feb 9.

Laboratory of Hematology and Flow Cytometry, CHU Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40487-017-0041-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488115PMC
February 2017